Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Does stereotactic ablative body radiotherapy (SABR) added to continued systemic therapy improve time to treatment failure compared with physician’s choice of systemic therapy in oligoprogressive ER-positive, HER2-negative advanced breast cancer? Study protocol for a multicentre, randomised, open-label phase II trial in Australian tertiary cancer centres (AVATAR-II). Local targets link to admitted publications; unresolved targets remain external evidence.
Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
10.1186/s12885-021-08042-w · 2021 · External reference
Stereotactic Ablative Body Radiotherapy (SABR) for Oligoprogressive ER-Positive Breast Cancer (AVATAR): A Phase II Prospective Multicenter Trial
10.1016/j.ijrobp.2023.08.033 · 2023 · External reference
10.1200/jco.2016.67.1487
10.1200/jco.2016.67.1487 · External reference
Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy
10.1155/2017/1367159 · 2017 · External reference
The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?
10.1016/j.clon.2019.05.015 · 2019 · External reference
Stereotactic body radiotherapy for oligoprogressive cancer
10.1259/bjr.20160251 · 2016 · External reference
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
10.1016/s0140-6736(23)01857-3 · 2024 · External reference
The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis
10.1016/j.clon.2017.04.035 · 2017 · External reference
10.1097/jto.0b013e3182745948
10.1097/jto.0b013e3182745948 · External reference
First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
10.7150/jca.26494 · 2019 · External reference
Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation
10.1016/j.cllc.2017.04.002 · 2017 · External reference
10.1200/jco.2014.56.7412
10.1200/jco.2014.56.7412 · External reference
10.1093/annonc/mdy155
10.1093/annonc/mdy155 · External reference
10.1016/s1470-2045(18)30292-4
10.1016/s1470-2045(18)30292-4 · External reference
10.1200/jco.2017.75.6155
10.1200/jco.2017.75.6155 · External reference
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
10.1038/s41523-018-0097-z · 2019 · External reference
10.1056/nejmoa1810527
10.1056/nejmoa1810527 · External reference
10.1200/jco.2017.73.7585
10.1200/jco.2017.73.7585 · External reference
10.1056/nejmoa1911149
10.1056/nejmoa1911149 · External reference
10.1038/s41591-021-01562-9
10.1038/s41591-021-01562-9 · External reference
10.1093/annonc/mdl341
10.1093/annonc/mdl341 · External reference
10.1016/s1470-2045(13)70322-x
10.1016/s1470-2045(13)70322-x · External reference
Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data
10.1093/oncolo/oyac075 · 2022 · External reference
10.1111/joim.12084
10.1111/joim.12084 · External reference
10.1016/s0140-6736(18)32487-5
10.1016/s0140-6736(18)32487-5 · External reference
Breast cancer is a systemic disease rather than an anatomical process
10.1007/s10549-017-4104-0 · 2017 · External reference
10.1007/s10549-016-4066-7
10.1007/s10549-016-4066-7 · External reference
The evolution of paradigms for the management of breast cancer: a personal perspective
1992 · External reference
Judging a Fish by Its Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative Local Treatments of Oligometastatic Cancer
10.1002/onco.13747 · 2021 · External reference
Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with “curative” intent
10.1016/j.lungcan.2019.12.019 · 2020 · External reference
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
10.1186/s40425-019-0672-3 · 2019 · External reference
Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade
2020 · External reference
Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer
10.1007/s12094-018-02005-7 · 2019 · External reference
10.1097/corr.0000000000000923
10.1097/corr.0000000000000923 · External reference
10.1007/s11999-010-1326-4
10.1007/s11999-010-1326-4 · External reference
10.1097/00000421-198212000-00014
10.1097/00000421-198212000-00014 · External reference
10.1200/jco.1997.15.3.974
10.1200/jco.1997.15.3.974 · External reference
